

To ensure that the lower number of subjects who had baseline scans as compared to the number of subjects who had follow-up scans did not affect the overall results of this study, all analyses were also conducted on the subset of patients who had a baseline and at least one follow up scan. All healthy controls had data from baseline and weeks 48, and 96, so there was no change in the results from this cohort. The percent changes with time, time x treatment interaction p values, and ANOVA p values for both the full data set and the subset of subjects that had baseline scans are listed in the table below. The results listed below are very similar to those given in Table 3 in the body of the article.

Supplemental Table 1. Comparison of full study results with the subset of MS subjects who had baseline plus at least one follow up scan. p values less than 0.05 are highlighted in bold.

Metabolite	Data Subset in Analysis	Relapsing MS Patients			ANOVA Between Cohorts (p)
		Ocrelizumab Treated	Interferon Beta-1a Treated	Time x Treatment Interaction (p)	
NAA/tCr	Full	4.4 (0.8 to 8.1) %	-1.3 (-5.2 to 2.5) %	0.04	0.09
	With Baseline	4.4 (0.7 to 8.1) %	-1.3 (-5.2 to 2.5) %	0.06	0.10
NAA	Full	3.9 (-0.5 to 8.3) %	1.8 (-2.8 to 6.4) %	0.45	0.44
	With Baseline	3.9 (-0.4 to 8.2) %	1.8 (-2.7 to 6.3) %	0.26	0.34
tCr	Full	-0.3 (-4.5 to 4.0) %	3.6 (-0.8 to 8.0) %	0.06	0.12
	With Baseline	-0.3 (-4.3 to 3.8) %	3.6 (-0.6 to 7.9) %	0.05	0.07
mI	Full	-6.0 (-12.2 to 0.3) %	5.9 (-0.6 to 12.5) %	0.06	0.03
	With Baseline	-6.0 (-11.8 to -0.09)%	5.9 (-0.2 to 12.1)%	0.04	0.01
tCho	Full	0.1 (-5.2 to 5.4) %	4.6 (-0.9 to 10.1) %	0.17	0.17
	With Baseline	0.1 (-5.1 to 5.2)%	4.6 (-0.8 to 10.0)%	0.14	0.11

